Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 248

1.

The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study.

Chan JK, Tian C, Fleming GF, Monk BJ, Herzog TJ, Kapp DS, Bell J.

Gynecol Oncol. 2010 Mar;116(3):301-6. doi: 10.1016/j.ygyno.2009.10.073. Epub 2009 Nov 28.

PMID:
19945740
2.

Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study.

Chan JK, Tian C, Teoh D, Monk BJ, Herzog T, Kapp DS, Bell J.

Gynecol Oncol. 2010 Mar;116(3):307-11. doi: 10.1016/j.ygyno.2009.10.074. Epub 2009 Nov 27.

PMID:
19944452
3.

Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.

Chan JK, Tian C, Monk BJ, Herzog T, Kapp DS, Bell J, Young RC; Gynecologic Oncology Group.

Cancer. 2008 May 15;112(10):2202-10. doi: 10.1002/cncr.23390.

4.

For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging?

Dizon DS, Restivo A, Lomme M, Charbonneau N, Brard L, Hughes T, Weitzen S, Legare R, Granai CO, Disilvestro P.

Am J Clin Oncol. 2008 Feb;31(1):39-42. doi: 10.1097/COC.0b013e318134ee6f.

PMID:
18376226
5.

Decreased dose density of standard chemotherapy does not compromise survival for ovarian cancer patients.

Molckovsky A, Vijay SM, Hopman WM, Bryson P, Jeffrey JF, Biagi JJ.

Int J Gynecol Cancer. 2008 Jan-Feb;18(1):8-13. Epub 2007 May 19.

PMID:
17511802
6.

Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.

Winter WE 3rd, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, Rubin SC, Muggia F, McGuire WP; Gynecologic Oncology Group.

J Clin Oncol. 2008 Jan 1;26(1):83-9. Epub 2007 Nov 19.

PMID:
18025437
7.

The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma.

Le T, Adolph A, Krepart GV, Lotocki R, Heywood MS.

Gynecol Oncol. 2002 May;85(2):351-5.

PMID:
11972399
8.

Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study.

Bell J, Brady MF, Young RC, Lage J, Walker JL, Look KY, Rose GS, Spirtos NM; Gynecologic Oncology Group.

Gynecol Oncol. 2006 Sep;102(3):432-9. Epub 2006 Jul 24.

PMID:
16860852
9.

First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up.

Fujiwara K, Sakuragi N, Suzuki S, Yoshida N, Maehata K, Nishiya M, Koshida T, Sawai H, Aotani E, Kohno I.

Gynecol Oncol. 2003 Sep;90(3):637-43. Erratum in: Gynecol Oncol. 2003 Dec;91(3):662.

PMID:
13678738
10.

Primary intravenous paclitaxel and platinum chemotherapy for high-risk Stage I epithelial ovarian carcinoma.

Chi DS, Waltzman RJ, Barakat RR, Spriggs DR.

Eur J Gynaecol Oncol. 1999;20(4):277-80.

PMID:
10475122
11.

Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.

Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, Franchi M, Tateo S, Zanetta G, Scarfone G, Giurgea L, Timmers P, Coens C, Pecorelli S; EORTC-ACTION collaborators. European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm.

J Natl Cancer Inst. 2003 Jan 15;95(2):113-25.

PMID:
12529344
12.

Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group.

Bamias A, Papadimitriou C, Efstathiou E, Rodolakis A, Vlahos G, Voulgaris Z, Bozas G, Fountzilas G, Aravantinos G, Razis E, Gika D, Dimopoulos MA.

BMC Cancer. 2006 Sep 25;6:228.

13.
14.

Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.

Pectasides D, Fountzilas G, Aravantinos G, Kalofonos C, Efstathiou H, Farmakis D, Skarlos D, Pavlidis N, Economopoulos T, Dimopoulos MA.

Gynecol Oncol. 2006 Aug;102(2):285-91. Epub 2006 Mar 3.

PMID:
16516283
15.

International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer.

Colombo N, Guthrie D, Chiari S, Parmar M, Qian W, Swart AM, Torri V, Williams C, Lissoni A, Bonazzi C; International Collaborative Ovarian Neoplasm (ICON) collaborators.

J Natl Cancer Inst. 2003 Jan 15;95(2):125-32.

PMID:
12529345
17.

The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy.

Skirnisdóttir I, Seidal T, Gerdin E, Sorbe B.

Int J Gynecol Cancer. 2002 May-Jun;12(3):265-76.

PMID:
12060448
18.

Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.

Pectasides D, Fountzilas G, Aravantinos G, Kalofonos HP, Efstathiou E, Salamalekis E, Farmakis D, Skarlos D, Briasoulis E, Economopoulos T, Dimopoulos MA.

Gynecol Oncol. 2005 May;97(2):436-41.

PMID:
15863142
19.

Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers.

Chan JK, Teoh D, Hu JM, Shin JY, Osann K, Kapp DS.

Gynecol Oncol. 2008 Jun;109(3):370-6. doi: 10.1016/j.ygyno.2008.02.006. Epub 2008 Apr 18.

PMID:
18395777
20.

A systematic overview of chemotherapy effects in ovarian cancer.

Högberg T, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):340-60. Review.

PMID:
11441940

Supplemental Content

Support Center